Large-scale genome-wide meta-analysis of polycystic ovary syndrome suggests shared genetic architecture for different diagnosis criteria

Polycystic ovary syndrome (PCOS) is a disorder characterized by hyperandrogenism, ovulatory dysfunction and polycystic ovarian morphology. Affected women frequently have metabolic disturbances including insulin resistance and dysregulation of glucose homeostasis. PCOS is diagnosed with two different...

Full description

Saved in:
Bibliographic Details
Published inPLoS genetics Vol. 14; no. 12; p. e1007813
Main Authors Day, Felix, Karaderi, Tugce, Jones, Michelle R, Meun, Cindy, He, Chunyan, Drong, Alex, Kraft, Peter, Lin, Nan, Huang, Hongyan, Broer, Linda, Magi, Reedik, Saxena, Richa, Laisk, Triin, Urbanek, Margrit, Hayes, M Geoffrey, Thorleifsson, Gudmar, Fernandez-Tajes, Juan, Mahajan, Anubha, Mullin, Benjamin H, Stuckey, Bronwyn G A, Spector, Timothy D, Wilson, Scott G, Goodarzi, Mark O, Davis, Lea, Obermayer-Pietsch, Barbara, Uitterlinden, André G, Anttila, Verneri, Neale, Benjamin M, Jarvelin, Marjo-Riitta, Fauser, Bart, Kowalska, Irina, Visser, Jenny A, Andersen, Marianne, Ong, Ken, Stener-Victorin, Elisabet, Ehrmann, David, Legro, Richard S, Salumets, Andres, McCarthy, Mark I, Morin-Papunen, Laure, Thorsteinsdottir, Unnur, Stefansson, Kari, Styrkarsdottir, Unnur, Perry, John R B, Dunaif, Andrea, Laven, Joop, Franks, Steve, Lindgren, Cecilia M, Welt, Corrine K
Format Journal Article
LanguageEnglish
Published United States Public Library of Science 19.12.2018
Public Library of Science (PLoS)
Subjects
Online AccessGet full text

Cover

Loading…
More Information
Summary:Polycystic ovary syndrome (PCOS) is a disorder characterized by hyperandrogenism, ovulatory dysfunction and polycystic ovarian morphology. Affected women frequently have metabolic disturbances including insulin resistance and dysregulation of glucose homeostasis. PCOS is diagnosed with two different sets of diagnostic criteria, resulting in a phenotypic spectrum of PCOS cases. The genetic similarities between cases diagnosed based on the two criteria have been largely unknown. Previous studies in Chinese and European subjects have identified 16 loci associated with risk of PCOS. We report a fixed-effect, inverse-weighted-variance meta-analysis from 10,074 PCOS cases and 103,164 controls of European ancestry and characterisation of PCOS related traits. We identified 3 novel loci (near PLGRKT, ZBTB16 and MAPRE1), and provide replication of 11 previously reported loci. Only one locus differed significantly in its association by diagnostic criteria; otherwise the genetic architecture was similar between PCOS diagnosed by self-report and PCOS diagnosed by NIH or non-NIH Rotterdam criteria across common variants at 13 loci. Identified variants were associated with hyperandrogenism, gonadotropin regulation and testosterone levels in affected women. Linkage disequilibrium score regression analysis revealed genetic correlations with obesity, fasting insulin, type 2 diabetes, lipid levels and coronary artery disease, indicating shared genetic architecture between metabolic traits and PCOS. Mendelian randomization analyses suggested variants associated with body mass index, fasting insulin, menopause timing, depression and male-pattern balding play a causal role in PCOS. The data thus demonstrate 3 novel loci associated with PCOS and similar genetic architecture for all diagnostic criteria. The data also provide the first genetic evidence for a male phenotype for PCOS and a causal link to depression, a previously hypothesized comorbid disease. Thus, the genetics provide a comprehensive view of PCOS that encompasses multiple diagnostic criteria, gender, reproductive potential and mental health.
Bibliography:ObjectType-Article-2
SourceType-Scholarly Journals-1
ObjectType-Feature-1
content type line 23
Members of the 23andMe Research team are employees of and hold stock or stock options in 23andMe, Inc. GT, UT, KS, and US are employees of deCODE genetics/Amgen Inc. MIM serves on advisory panels for Pfizer and NovoNordisk. MIM has received honoraria from Pfizer, NovoNordisk and EliLilly, and has received research funding from Pfizer, NovoNordisk, EliLilly, AstraZeneca, Sanofi Aventis, Boehringer Ingelheim, Merck, Roche, Janssen, Takeda, and Servier. JL has received consultancy fees from Danone, Metagenics inc., Titus Healthcare, Roche and Euroscreen. CW is a consultant for Novartis and has received UptoDate royalties.
Authors from 23andMe are provided in the Acknowledgments.
ISSN:1553-7404
1553-7390
1553-7404
DOI:10.1371/journal.pgen.1007813